Nomura Holdings Inc. Reduces Holdings in Stryker Corporation $SYK

Nomura Holdings Inc. lowered its position in shares of Stryker Corporation (NYSE:SYK) by 50.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,600 shares of the medical technology company’s stock after selling 7,758 shares during the period. Nomura Holdings Inc.’s holdings in Stryker were worth $3,007,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Norges Bank acquired a new position in Stryker during the second quarter worth approximately $1,882,173,000. Alliancebernstein L.P. grew its position in shares of Stryker by 307.6% during the second quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock worth $2,214,146,000 after acquiring an additional 4,223,366 shares during the last quarter. Corient Private Wealth LLC increased its holdings in shares of Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the period. Price T Rowe Associates Inc. MD raised its position in Stryker by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after purchasing an additional 1,021,496 shares during the last quarter. Finally, ABN AMRO Bank N.V. acquired a new stake in Stryker during the 2nd quarter worth $191,047,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Redburn Partners set a $420.00 price objective on shares of Stryker in a research note on Thursday, September 18th. Needham & Company LLC reissued a “buy” rating and set a $448.00 price target on shares of Stryker in a report on Friday, November 14th. UBS Group set a $408.00 price objective on Stryker in a research note on Monday, October 13th. Truist Financial increased their price objective on Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research report on Friday, November 14th. Finally, Evercore ISI dropped their target price on Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Twelve analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $431.83.

Stryker Price Performance

Shares of SYK opened at $355.34 on Tuesday. The company has a current ratio of 1.85, a quick ratio of 1.13 and a debt-to-equity ratio of 0.68. The stock’s 50 day moving average is $366.60 and its two-hundred day moving average is $378.26. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The firm has a market capitalization of $135.89 billion, a PE ratio of 46.69, a P/E/G ratio of 2.51 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. This is an increase from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Wednesday, December 31st. Stryker’s dividend payout ratio is 44.15%.

Insiders Place Their Bets

In other news, CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at $2,449,200.72. This represents a 2.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. This represents a 9.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 522,118 shares of company stock worth $185,381,932. Corporate insiders own 5.20% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.